SANUWAVE Health, Inc. (SNWV) 株式分析

企業概要

SANUWAVE Health, Inc. is a specialized medical device firm that commercializes regenerative medicines utilizing noninvasive ultrasound or shockwave technology to stimulate tissue repair and regeneration. The company operates within the Healthcare sector, specifically the Medical Devices industry, positioning itself to serve a market focused on advanced therapeutic interventions. Its current scale is defined by a market capitalization of $151.26M and an annual revenue (TTM) of $44.05M, supported by a workforce of 55 employees. These financial metrics indicate a small-cap enterprise that has achieved significant profitability relative to its size, suggesting a niche market position where the company generates substantial returns per employee and manages its capital base efficiently.

財務健全性

The company reported a revenue (TTM) of $44.05M and net income (TTM) of $11.81M, while EBITDA stands at $7.49M. The gap between the $44.05M in revenue and the $11.81M in net income reveals a highly efficient cost structure, as the company retains over 26% of its top line as profit after all expenses. However, the free cash flow is reported at $-6,454,750, which indicates a period of cash consumption likely driven by capital expenditures or working capital requirements rather than operational inefficiency. Despite the negative free cash flow, the balance sheet holds $11.96M in cash against $22.97M in total debt, resulting in a debt-to-equity ratio of 1418.84. This high leverage ratio suggests the company is heavily reliant on equity financing or retains earnings to fund operations rather than traditional long-term debt service. The current ratio of 1.38 demonstrates that the company possesses sufficient current assets to cover its current liabilities, indicating adequate short-term liquidity to meet immediate obligations. Furthermore, the Return on Assets is 12.1%, while Return on Equity is listed as N/A due to the leverage dynamics affecting the equity base calculation. These return metrics reveal that management is effectively utilizing its asset base to generate income, even as the high debt levels distort standard equity return calculations.

バリュエーション評価

The trailing twelve-month P/E ratio is 42.93, whereas the forward P/E is -1760.00, implying that expected earnings growth or future profitability assumptions have not yet materialized to support a positive forward multiple. The price-to-book ratio stands at 93.62, indicating that the market values the company at a significant premium over its net book value, reflecting high expectations for future growth or intangible asset value. Alternative valuation metrics such as the price-to-sales ratio of 3.43 and an EV/EBITDA of 21.68 suggest the market is pricing the stock based on revenue generation and earnings power rather than traditional equity multiples. The stock has traded between a 52-week high of $46.59 and a 52-week low of $16.27, placing the current valuation within a wide historical range that reflects significant price volatility. With a beta of 1.51, the stock exhibits price volatility that is more than 50% higher than the broader market, indicating sensitivity to sector-specific risks and broader market fluctuations.

Growth & Income

Revenue growth (YoY) is reported at 26.8%, while earnings growth (YoY) is listed as N/A, suggesting that the company is currently scaling revenue without the historical earnings data required to calculate year-over-year earnings growth percentages. As the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders, meaning all net income is retained to fund operations, debt reduction, or reinvestment into the regenerative medicine technology. This reinvestment strategy is typical for growth-stage medical device companies that prioritize expanding their product portfolio and clinical trials over providing immediate income to investors. Overall, the company presents a growth-oriented profile characterized by strong revenue expansion but lacks a current dividend income stream for investors seeking passive yield.